Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Population pharmacokinetics and exposure-response relationship of trastuzumab and bevacizumab in early-stage breast cancer

Autor: A, Petitcollin, N, Azzopardi, J Y, Pierga, D, Ternant, I, Navarro-Teulon, C, Desvignes, M A, Mouret-Reynier, B, Coudert, G, Paintaud

Publikováno v: European journal of clinical pharmacology. 77(12)

To describe the sources of interindividual variability of bevacizumab and trastuzumab pharmacokinetics in early-stage breast cancer, and to study the relationship between exposure and both early clinical response and specific adverse events.Patients

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::e0e87f60aeae5bd13e1274034d1d90d6
https://pubmed.ncbi.nlm.nih.gov/34245336

425P Cetuximab could be administered once every two weeks instead of once weekly

Autor: M. Caulet, Olivier Capitain, Nicolas Azzopardi, Thierry Lecomte, David Tougeron, D. Ternant, Romain Chautard, G. Paintaud, Michèle Boisdron-Celle, C. Passot, S. Lobet, C. Vignault-Desvignes

Publikováno v: Annals of Oncology. 32:S547

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8599e37a208eee88f357ee663167eabc
https://doi.org/10.1016/j.annonc.2021.08.946

PO-0702: Phase I trial evaluating panitumumab in combination with chemoradiotherapy for anal cancers

Autor: Gérard Lledo, Emilie Maillard, C. Levy-Piedbois, Antoine Adenis, C. Lemanski, Véronique Vendrely, Sylvain Manfredi, Eric Terrebonne, Xavier Mirabel, Thierry Lecomte, G. Paintaud, Laetitia Dahan, E. Le Prisé, V. Mammar, Thomas Aparicio

Publikováno v: ESTRO 36
ESTRO 36, May 2017, Vienne, Austria. Radiotherapy and Oncology, 123 (Supplement 1), pp.S367-S368, 2017, ESTRO 36, May 5-9, 2017, Vienna, Austria. 〈http://www.sciencedirect.com/science/article/pii/S0167814017311398?via%3Dihub〉. 〈10.1016/S0167-8140(17)31139-8〉
ESTRO 36, May 2017, Vienne, Austria., Radiotherapy and Oncology, 123 (Supplement 1), pp.S367-S368, 2017, ESTRO 36, May 5-9, 2017, Vienna, Austria. ⟨10.1016/S0167-8140(17)31139-8⟩
ESTRO 36, May 2017, Vienne, Austria. Radiotherapy and Oncology, 123 (Supplement 1), pp.S367-S368, 2017, ESTRO 36, May 5-9, 2017, Vienna, Austria. ⟨10.1016/S0167-8140(17)31139-8⟩

IF 4.328; International audience

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b797323de9e6b35b246143edec69bd3
https://hal-univ-bourgogne.archives-ouvertes.fr/hal-01685153

La pharmacogénétique moléculaire hospitalière en France : données actuelles et perspectives

Autor: L. Becquemont, Franck Broly, Pierre Marquet, Nicolas Picard, S. Loric, Marie-Anne Loriot, B. Namour, C.-M. Dhaneens, M.-C. Gagnieu, X. Fonrose, Jean-Christophe Boyer, Alain Morel, S. Bezieau, G. Paintaud, E. Jacqz-Aigrain, C. Verstuyft, K. Peoc’h, H. Watier, M. Boisdron-Celle, Delphine Allorge, Erick Gamelin, C. Gozé, G. Bessard, P.-H. Beaune

Publikováno v: Annales Pharmaceutiques Françaises. 65:371-381

Resume Des unites de pharmacogenetique moleculaire se sont mises en place au sein de laboratoires hospitaliers francais. L’impact clinique de ces nouvelles structures est encore limite et de nombreuses questions d’ordre organisationnel, ethique,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f6e87c120457deee0317e636366374ee
https://doi.org/10.1016/s0003-4509(07)74196-2